1. Home
  2. Pharma and Healthcare
  3. Reports Details

Infliximab (trade names Remicade among others) is a chimeric monoclonal antibody biologic drug that works against tumor necrosis factor alpha (TNF-?) and is used to treat autoimmune diseases.

This report studies the global Infliximab and biosimilar market status and forecast, categorizes the global Infliximab and biosimilar market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

The major manufacturers covered in this report

    Janssen Biotech

    Merck and Co.

    Pfizer

Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering

    North America

    Europe

    China

    Japan

    Southeast Asia

    India

We can also provide the customized separate regional or country-level reports, for the following regions:

    North America

       United States

       Canada

       Mexico

    Asia-Pacific

       China

       India

       Japan

       South Korea

       Australia

       Indonesia

       Singapore

       Rest of Asia-Pacific

    Europe

       Germany

       France

       UK

       Italy

       Spain

       Russia

       Rest of Europe

    Central & South America

       Brazil

       Argentina

       Rest of South America

    Middle East & Africa

       Saudi Arabia

       Turkey

       Rest of Middle East & Africa

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

    Infliximab

    infliximab-dyyb

    infliximab-abda

On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including

    Crohn's Disease

    Pediatric Crohn's Disease

    Ulcerative Colitis

    Rheumatoid Arthritis

    Ankylosing Spondylitis

    Psoriatic Arthritis

    Plaque Psoriasis

The study objectives of this report are:

    To analyze and study the global Infliximab and biosimilar capacity, production, value, consumption, status (2013-2017) and forecast (2018-2025);

    Focuses on the key Infliximab and biosimilar manufacturers, to study the capacity, production, value, market share and development plans in future.

    Focuses on the global key manufacturers, to define, describe and analyze the market competition landscape, SWOT analysis.

    To define, describe and forecast the market by type, application and region.

    To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.

    To identify significant trends and factors driving or inhibiting the market growth.

    To analyze the opportunities in the market for stakeholders by identifying the high growth segments.

    To strategically analyze each submarket with respect to individual growth trend and their contribution to the market

    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

    To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Infliximab and biosimilar are as follows:

    History Year: 2013-2017

    Base Year: 2017

    Estimated Year: 2018

    Forecast Year 2018 to 2025

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders

Infliximab and biosimilar Manufacturers

Infliximab and biosimilar Distributors/Traders/Wholesalers

Infliximab and biosimilar Subcomponent Manufacturers

Industry Association

Downstream Vendors

Available Customizations

With the given market data, QYResearch offers customizations according to the company's specific needs. The following customization options are available for the report:

Regional and country-level analysis of the Infliximab and biosimilar market, by end-use.

Detailed analysis and profiles of additional market players.

Table of Contents

Table of Contents

Global Infliximab and biosimilar Market Research Report 2018

1 Infliximab and biosimilar Market Overview

    1.1 Product Overview and Scope of Infliximab and biosimilar

    1.2 Infliximab and biosimilar Segment by Type (Product Category)

       1.2.1 Global Infliximab and biosimilar Production and CAGR (%) Comparison by Type (Product Category)(2013-2025)

       1.2.2 Global Infliximab and biosimilar Production Market Share by Type (Product Category) in 2017

       1.2.3 Infliximab

       1.2.3 infliximab-dyyb

         infliximab-abda

    1.3 Global Infliximab and biosimilar Segment by Application

       1.3.1 Infliximab and biosimilar Consumption (Sales) Comparison by Application (2013-2025)

       1.3.2 Crohn's Disease

       1.3.3 Pediatric Crohn's Disease

       1.3.4 Ulcerative Colitis

       1.3.5 Rheumatoid Arthritis

       1.3.6 Ankylosing Spondylitis

       1.3.7 Psoriatic Arthritis

       1.3.8 Plaque Psoriasis

    1.4 Global Infliximab and biosimilar Market by Region (2013-2025)

       1.4.1 Global Infliximab and biosimilar Market Size (Value) and CAGR (%) Comparison by Region (2013-2025)

       1.4.2 North America Status and Prospect (2013-2025)

       1.4.3 Europe Status and Prospect (2013-2025)

       1.4.4 China Status and Prospect (2013-2025)

       1.4.5 Japan Status and Prospect (2013-2025)

       1.4.6 Southeast Asia Status and Prospect (2013-2025)

       1.4.7 India Status and Prospect (2013-2025)

    1.5 Global Market Size (Value) of Infliximab and biosimilar (2013-2025)

       1.5.1 Global Infliximab and biosimilar Revenue Status and Outlook (2013-2025)

       1.5.2 Global Infliximab and biosimilar Capacity, Production Status and Outlook (2013-2025)

2 Global Infliximab and biosimilar Market Competition by Manufacturers

    2.1 Global Infliximab and biosimilar Capacity, Production and Share by Manufacturers (2013-2018)

       2.1.1 Global Infliximab and biosimilar Capacity and Share by Manufacturers (2013-2018)

       2.1.2 Global Infliximab and biosimilar Production and Share by Manufacturers (2013-2018)

    2.2 Global Infliximab and biosimilar Revenue and Share by Manufacturers (2013-2018)

    2.3 Global Infliximab and biosimilar Average Price by Manufacturers (2013-2018)

    2.4 Manufacturers Infliximab and biosimilar Manufacturing Base Distribution, Sales Area and Product Type

    2.5 Infliximab and biosimilar Market Competitive Situation and Trends

       2.5.1 Infliximab and biosimilar Market Concentration Rate

       2.5.2 Infliximab and biosimilar Market Share of Top 3 and Top 5 Manufacturers

       2.5.3 Mergers & Acquisitions, Expansion

3 Global Infliximab and biosimilar Capacity, Production, Revenue (Value) by Region (2013-2018)

    3.1 Global Infliximab and biosimilar Capacity and Market Share by Region (2013-2018)

    3.2 Global Infliximab and biosimilar Production and Market Share by Region (2013-2018)

    3.3 Global Infliximab and biosimilar Revenue (Value) and Market Share by Region (2013-2018)

    3.4 Global Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

    3.5 North America Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

    3.6 Europe Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

    3.7 China Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

    3.8 Japan Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

    3.9 Southeast Asia Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

    3.10 India Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

4 Global Infliximab and biosimilar Supply (Production), Consumption, Export, Import by Region (2013-2018)

    4.1 Global Infliximab and biosimilar Consumption by Region (2013-2018)

    4.2 North America Infliximab and biosimilar Production, Consumption, Export, Import (2013-2018)

    4.3 Europe Infliximab and biosimilar Production, Consumption, Export, Import (2013-2018)

    4.4 China Infliximab and biosimilar Production, Consumption, Export, Import (2013-2018)

    4.5 Japan Infliximab and biosimilar Production, Consumption, Export, Import (2013-2018)

    4.6 Southeast Asia Infliximab and biosimilar Production, Consumption, Export, Import (2013-2018)

    4.7 India Infliximab and biosimilar Production, Consumption, Export, Import (2013-2018)

5 Global Infliximab and biosimilar Production, Revenue (Value), Price Trend by Type

    5.1 Global Infliximab and biosimilar Production and Market Share by Type (2013-2018)

    5.2 Global Infliximab and biosimilar Revenue and Market Share by Type (2013-2018)

    5.3 Global Infliximab and biosimilar Price by Type (2013-2018)

    5.4 Global Infliximab and biosimilar Production Growth by Type (2013-2018)

6 Global Infliximab and biosimilar Market Analysis by Application

    6.1 Global Infliximab and biosimilar Consumption and Market Share by Application (2013-2018)

    6.2 Global Infliximab and biosimilar Consumption Growth Rate by Application (2013-2018)

    6.3 Market Drivers and Opportunities

       6.3.1 Potential Applications

       6.3.2 Emerging Markets/Countries

7 Global Infliximab and biosimilar Manufacturers Profiles/Analysis

    7.1 Janssen Biotech

       7.1.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

       7.1.2 Infliximab and biosimilar Product Category, Application and Specification

            7.1.2.1 Product A

            7.1.2.2 Product B

       7.1.3 Janssen Biotech Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

       7.1.4 Main Business/Business Overview

    7.2 Merck and Co.

       7.2.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

       7.2.2 Infliximab and biosimilar Product Category, Application and Specification

            7.2.2.1 Product A

            7.2.2.2 Product B

       7.2.3 Merck and Co. Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

       7.2.4 Main Business/Business Overview

    7.3 Pfizer

       7.3.1 Company Basic Information, Manufacturing Base, Sales Area and Its Competitors

       7.3.2 Infliximab and biosimilar Product Category, Application and Specification

            7.3.2.1 Product A

            7.3.2.2 Product B

       7.3.3 Pfizer Infliximab and biosimilar Capacity, Production, Revenue, Price and Gross Margin (2013-2018)

       7.3.4 Main Business/Business Overview

8 Infliximab and biosimilar Manufacturing Cost Analysis

    8.1 Infliximab and biosimilar Key Raw Materials Analysis

       8.1.1 Key Raw Materials

       8.1.2 Price Trend of Key Raw Materials

       8.1.3 Key Suppliers of Raw Materials

       8.1.4 Market Concentration Rate of Raw Materials

    8.2 Proportion of Manufacturing Cost Structure

       8.2.1 Raw Materials

       8.2.2 Labor Cost

       8.2.3 Manufacturing Expenses

    8.3 Manufacturing Process Analysis of Infliximab and biosimilar

9 Industrial Chain, Sourcing Strategy and Downstream Buyers

    9.1 Infliximab and biosimilar Industrial Chain Analysis

    9.2 Upstream Raw Materials Sourcing

    9.3 Raw Materials Sources of Infliximab and biosimilar Major Manufacturers in 2017

    9.4 Downstream Buyers

10 Marketing Strategy Analysis, Distributors/Traders

    10.1 Marketing Channel

       10.1.1 Direct Marketing

       10.1.2 Indirect Marketing

       10.1.3 Marketing Channel Development Trend

    10.2 Market Positioning

       10.2.1 Pricing Strategy

       10.2.2 Brand Strategy

       10.2.3 Target Client

    10.3 Distributors/Traders List

11 Market Effect Factors Analysis

    11.1 Technology Progress/Risk

       11.1.1 Substitutes Threat

       11.1.2 Technology Progress in Related Industry

    11.2 Consumer Needs/Customer Preference Change

    11.3 Economic/Political Environmental Change

12 Global Infliximab and biosimilar Market Forecast (2018-2025)

    12.1 Global Infliximab and biosimilar Capacity, Production, Revenue Forecast (2018-2025)

       12.1.1 Global Infliximab and biosimilar Capacity, Production and Growth Rate Forecast (2018-2025)

       12.1.2 Global Infliximab and biosimilar Revenue and Growth Rate Forecast (2018-2025)

       12.1.3 Global Infliximab and biosimilar Price and Trend Forecast (2018-2025)

    12.2 Global Infliximab and biosimilar Production, Consumption , Import and Export Forecast by Region (2018-2025)

       12.2.1 North America Infliximab and biosimilar Production, Revenue, Consumption, Export and Import Forecast (2018-2025)

       12.2.2 Europe Infliximab and biosimilar Production, Revenue, Consumption, Export and Import Forecast (2018-2025)

       12.2.3 China Infliximab and biosimilar Production, Revenue, Consumption, Export and Import Forecast (2018-2025)

       12.2.4 Japan Infliximab and biosimilar Production, Revenue, Consumption, Export and Import Forecast (2018-2025)

       12.2.5 Southeast Asia Infliximab and biosimilar Production, Revenue, Consumption, Export and Import Forecast (2018-2025)

       12.2.6 India Infliximab and biosimilar Production, Revenue, Consumption, Export and Import Forecast (2018-2025)

    12.3 Global Infliximab and biosimilar Production, Revenue and Price Forecast by Type (2018-2025)

    12.4 Global Infliximab and biosimilar Consumption Forecast by Application (2018-2025)

13 Research Findings and Conclusion

14 Appendix

    14.1 Methodology/Research Approach

       14.1.1 Research Programs/Design

       14.1.2 Market Size Estimation

       14.1.3 Market Breakdown and Data Triangulation

    14.2 Data Source

       14.2.1 Secondary Sources

       14.2.2 Primary Sources

    14.3 Disclaimer

Request Sample

Related Reports

Latest Reports